Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis (Q38029995)

27 August 2017

Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis (English)

1 reference

27 August 2017

0 references

Emily E Sutton

1

1 reference

PubMed ID

22837347

27 August 2017

Daniel M Riche

series ordinal

2

1 reference

PubMed ID

22837347

27 August 2017

language of work or name

English

0 references

publication date

25 July 2012

1 reference

Annals of Pharmacotherapy

27 August 2017

1 reference

27 August 2017

46

1 reference

27 August 2017

7-8

1 reference

27 August 2017

1000-1009

1 reference

Prevalence and trends in low femur bone density among older US adults: NHANES 2005-2006 compared with NHANES III.

27 August 2017

1 reference

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis

21 January 2018

1 reference

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

21 January 2018

1 reference

Giant osteoclast formation and long-term oral bisphosphonate therapy

21 January 2018

1 reference

Denosumab in osteoporosis and oncology

21 January 2018

1 reference

Role of RANKL inhibition in osteoporosis

21 January 2018

1 reference

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

21 January 2018

1 reference

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

21 January 2018

1 reference

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

21 January 2018

1 reference

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

21 January 2018

1 reference

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass

21 January 2018

1 reference

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

21 January 2018

1 reference

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density

21 January 2018

1 reference

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

A meta-analysis of osteoporotic fracture risk with medication nonadherence

21 January 2018

1 reference

21 January 2018

1 reference

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

21 January 2018

1 reference

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1Q543

1 reference

27 August 2017

1 reference

PubMed ID

22837347